Drug Trial Radar · NCT05587894
OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
256
Planned (sponsor's estimate)
Start
Apr 27, 2023
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- ANRS, Emerging Infectious DiseasesGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Oct 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The overall purpose of the trial is to evaluate the efficacy and safety of possible combination antiviral therapy DAA (remdesivir + nirmatrelvir/r)∞ versus the reference monotherapy (nirmatrelvir/r alone) and to assess the efficacy and safety of increasing the nirmatrelvir/r course from 5- to 10 days in immunocompromised patients diagnosed with asymptomatic or mild to moderate COVID-19.
Conditions
- COVID-19
- Immunodeficiency
Interventions
Paxlovid 5 daysDrug
Nirmatrelvir/r 300mg/100 mg bid will be given for 5 days, orally. Nirmatrelvir/r is a combination of two molecules: nirmatrelvir which is a protease inhibitor (against 3CL) and ritonavir which has a booster role. Nirmatrelvir/r (marketed by Pfizer under the brand name Paxlovid®) is indicated for the treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.
Paxlovid 10 daysDrug
Nirmatrelvir/r 300mg/100 mg bid will be given for 10 days, orally.
VekluryDrug
Remdesivir "flash", 200mg, intravenous. Remdesivir (marketed by Gilead under de brand name Veklury®) is indicated in patients with pneumonia requiring supplemental oxygen (inpatients), as well as in outpatients who are at increased risk of progressing to severe COVID-19. The mode of action characterize remdesivir as a direct-acting antiviral compound.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of patients with SARS-CoV-2 viral load (threshold cicle (Ct) <32) by real-time RT-PCR in nasopharyngeal swabs at Day 10 after treatment initiation.Time frame: Day 10
Locations
18 sites in 3 countries. Site status is shown where the registry gives one.
Saint-André Hospital
Bordeaux, Bordeaux, France · Recruiting
Pellegrin Hospital
Bordeaux, Bordeaux, France · Recruiting
Francois Mitterrand Hospital
Dijon, Dijon, France · Recruiting
Croix Rousse Hospital
Lyon, Lyon, France · Recruiting
La Colombière Hospital
Montpellier, Montpellier, France · Recruiting
Hotel Dieu Hospital
Nantes, Nantes, France · Recruiting
Laribosière Hospital
Paris, Paris, France · Recruiting
Saint Antoine Hospital
Paris, Paris, France · Recruiting
Pitié-Salpêtrière Hospital
Paris, Paris, France · Recruiting
Saint Louis Hospital
Paris, Paris, France · Recruiting
Bichat Claude-Bernard Hospital
Paris, Paris, France · Recruiting
Robert Debré Hospital
Reims, Reims, France · Recruiting
Purpan Hospital
Toulouse, Toulouse, France · Recruiting
Tourcoing Hospital
Tourcoing, Tourcoing, France · Recruiting
Division of Infectious Diseases, Verona University Hospital
Verona, Italy · Recruiting
Drammen Hospital, Vestre Viken Hospital
Drammen, Norway · Recruiting
Oslo University Hospital and University of Oslo
Oslo, Norway · Recruiting
Vestfold Hospital Trust
Tønsberg, Norway · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.